Mirae Asset Global Investments Co., Ltd. Verve Therapeutics, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

$20 Billion
Q2 2024

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 2,507 shares of VERV stock, worth $13,813. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,507

Previous 171,795 98.54%

Holding current value

$13,813

Previous $2.28 Million 99.47%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 30, 2024	SELL	$4.76 - $12.79 $805,810 - $2.17 Million	-169,288 Reduced 98.54%	2,507 $12,000
Q1 2024 May 01, 2024	BUY	$10.81 - $17.96 $638,157 - $1.06 Million	59,034 Added 52.35%	171,795 $2.28 Million
Q4 2023 Jan 24, 2024	SELL	$8.84 - $18.7 $878,192 - $1.86 Million	-99,343 Reduced 46.84%	112,761 $1.57 Million
Q3 2023 Oct 26, 2023	BUY	$11.42 - $20.82 $197,303 - $359,707	17,277 Added 8.87%	212,104 $2.81 Million
Q2 2023 Aug 10, 2023	BUY	$13.34 - $19.9 $345,252 - $515,031	25,881 Added 15.32%	194,827 $3.65 Million
Q1 2023 May 04, 2023	BUY	$14.3 - $24.01 $173,959 - $292,081	12,165 Added 7.76%	168,946 $2.44 Million
Q4 2022 Feb 09, 2023	BUY	$17.85 - $40.7 $356,678 - $813,267	19,982 Added 14.61%	156,781 $3.03 Million
Q3 2022 Nov 10, 2022	BUY	$15.63 - $41.49 $298,548 - $792,500	19,101 Added 16.23%	136,799 $4.7 Million
Q2 2022 Jul 26, 2022	BUY	$11.14 - $23.17 $1.31 Million - $2.73 Million	117,698 New	117,698 $1.8 Million

Others Institutions Holding VERV

# of Institutions

173

Shares Held

74.7M

Call Options Held

115K

Put Options Held

144K

View Full List

About Verve Therapeutics, Inc.

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $330M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

More about VERV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Account

Mirae Asset Global Investments Co., Ltd. Verve Therapeutics, Inc. Transaction History